Fig. 1From: The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer – a systematic reviewFlow of the search strategy. HER2+ human epidermal growth factor receptor 2 positive, mBC metastatic breast cancer, RCTs randomized controlled trialsBack to article page